%0
Generic
%T
Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study).
%A Motzer, Robert J.
%A Porta, Camillo
%A Eto, Masatoshi
%A Powles, Thomas
%A Grünwald, Viktor
%A Hutson, Thomas E.
%A Alekseev, Boris
%A Rha, Sun Young
%A Kopyltsov, Evgeny
%A Méndez Vidal, María José
%A Hong, Sung-Hoo
%A Kapoor, Anil
%A Alonso Gordoa, Teresa
%A Goh, Jeffrey C.
%A Merchan, Jaime R.
%A Smith, Alan D.
%A Mody, Kalgi
%A Perini, Rodolfo F.
%A Xing, Dongyuan
%A Choueiri, Toni K.
%I American Society of Clinical Oncology (ASCO)
%@ 0732-183X
%@ 1527-7755
%D 2021
%C American Society of Clinical Oncology (ASCO)
%U http://slubdd.de/katalog?TN_libero_mab2